Document O3yLzxY5yE8XvVxgKNrrNwX5w

f r , t Ti 'f i J - > orDEPAKixnrr Hatm, e d u c at e d *, a it o v z l p a r x Public Health Gcrvlce Occu;*tlcoal Health f* search A Training facility Bureau of state Service* lOlfc Broadway Cincinnati 2, Ohio July 87, Oordcc J. Otopp*. M.B. X. X. duPont d* Bemoure 4 CO. Ea*kU Labor*tori** Smrt, CiUn tear Dr. Btoppet Tour lnqulrlee regarding hypereueceptlblllty and lead polecolng bar* bom referred to m by Or. Stokiager. Is Prance and Italy, where aazty esplcyee* la the Induetry com fra* ethnic Croupe la vfclrh glucoee-6-pfcoephate dahydrogenaee deficiency of the erythro cyte 1* not uxowe, there bare been attempt# to determine If thl* Inborn error of netabollen va* factor la aggravating Mturalaa la thl* pptst of th* Industrial population. It bad teea *hcwo by Jooderto In Poland that rabbit* and m ezpoeed to load exhibited a reduction la the glutathione content of the red call, finally, two report* *how that lead poleoclng doe*. Indeed, depretei 1. the glacoae* 6-phoephate dehydrogenate (0-6 PI) of erythrocyte*, together with 2. glutath loot (OCH), 3 the ability of red cell glutathione to be restored after lacvibatloe with acetyl-pbenylhydrazlne. (the CoS (tab111ty teat). and laetly. b. the ability of the rad cell entyne *yetena to reeoorert w**vencglchln Into hemoglobin. Apparently lead lap*Ire the development of the erythrocyte ao that. among other defect#, the eniyme *y*t*aa which Maintain normal aeafcrao* and beaoglcbln Integrity are deficient. Objecting to lead erpoeure *ucb pereoo*. deficient In the normal canplemot of erythrocyte entyae*. would aggravate the defect aod lead to hemolytic effect* *ucb a* Iran,pi re vben pereon* with thee* Inborn error* of mtabollM are treated with a turner of cuacc drug* ae aeplrtn. acetanilide. *ulfae. etc. evidence for lead-a*o lated effect* on red cell conetltuente 1* reported by Pub loo, a. f., Coed*. 0. C.. Pvrelll, 0.. and Parlgl, A.. The Behavior of glutathione, the glutaUilcce etabillty teet and jlucoee-6-pfccepivat# dehydrogenaee activity in lead poltoclng (Comportamento dal glutatlooe. del & i Kjg& m& i "I i * * '! ' 1 0 Dr. Gordon <7. 8topj* - 7/27/66 tt dt tttblllt* dal glut*tlco doll' altirata gluc*io-6-foafato daldro(tiwiu Ml a*turnlolo), KlMm IMlci JV, J)H32 (1963) fWtult# of tbit vork tr# tuaatrlttd la a tablti 8ub>ctt 03H ag/lOQal r.b.e. osa tft*r ittb. tttt 0-6-P0 naltt/10^ rad ctllt 1. Boraal 57 6 k7 * 277 12 2. fb-clinical fftet* tout* tad tufctcvta ko 9 P <"0.0i 35 10 P < 0.01 231 31 p< 9.01 3. Sb txpottd, b o curt tyiiyt rot k7 11 f 03.05 but lb tad copros>on*iyrla ltvtttd la urlnt kl 8 P <"b.05 2k5 33 Pc 9.05 V tlblt .001 O.D./ala. Tfca function ef tat trjrtirocjfU toryat vita ra*pact to ntntlca of btao^iotia ji?jaot to It* eocnnlta to atthiar^iobln (M*tl;*o*icbla raductlco trt) bat bate obitml to ba l*3>*lra4 la Kut* lMd potaoaioft lilts Mis tad 7. 0. Etrlty, Cxptrlisct vltb u txttndtd MUao(lobU rtductloo tttt. factor* Influtocia* bao*lot la dtttructlon, Blood 27* 395 (1966* Mr). Vbllt tb*t author* Motion tbtlr lttd *tudlt, ooljr la rtftrrls* to toolbar rtport to bt publlabtd, thty do raport tbtt Mthtaclwbla rtductloo capacity v*i lap*1rad. Tbtlr tala tbctl* It tbtt btaoclobla It dt*tro7*d la tb* condition* of tba Utt tad tbit abculd bt tvtlutttd. Cbforiuonttly tbty e*ph**lt* tbit vbllt ttodlag to crtrlocb tbt l*r.ifleant fact tbtt Mtbaaotlobla ptrtltt* lcnar la dafactlv* hmoljrattt* of trythrocyta* (la tbit cat*, tatocltttd vltb 1% poltcalac) tbaa It dot* la baaolyttta* of norna.1 blood. Vbllt vi btva not bate tbit to do arttoalra lt*4 ttodlat la tbl* laboratory, v* btva ttudlcd tffact* of otbtr **oli ce tbt blood tnd tlauS*Vniyaa aysltna bf antaal*. V fctra c6n> dtflcltot tubjact* tvtlltblt Uirv^b loctl boapttal*. Tbt tnelottd pr<v/iur* for G6P0 activity tnd tbt *l -qutntltttIv* Mtbaaoglebta rtduetto** loi trt tbott v* h*r* found attUfactory. Truttln< tbit laforaatlon vtll bt uttful to jfw, Z m Cine inly your*, /l**d/ Jcfan T. Mount*la To* ieolo*y Cactlon wt .m. IW uu1.1'j * HgH8B*i:iywyaita.il") tfUM.'.i